IFUL Insightful Corp (MM)

Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced today that Medical Prognosis Institute (http://medical-prognosis.com), a provider of leading-edge technology based on DNA microarrays, has selected S-PLUS� 8 Enterprise Server, Insightful�s software platform for statistical data analysis and predictive analytics. Medical Prognosis Institute will utilize S-PLUS 8 Enterprise Server for deploying analytic models originally prototyped in R, the free open-source dialect of Insightful�s S language. �We selected S-PLUS after a thorough review of applicable technologies, including R which we have been using,� said Dr. Steen Knudsen, chief scientific officer of Medical Prognosis Institute. �Insightful�s S-PLUS server and the S+ArrayAnalyzer� solution provide a robust, extensible technology framework and are readily validated within our environment. In addition, I was very pleased that in less than 20 hours I was able to easily port our R code into S-PLUS for deployment with the S-PLUS server.� �In today�s highly competitive drug discovery and development environment, it�s crucial that life science companies arm themselves with the tools they need to both meet the requirements of a validated environment and provide significant gains in productivity and efficiency,� said Jeff Coombs, president and CEO of Insightful. �We are pleased that Medical Prognosis Institute has recognized what an asset S-PLUS can be and decided to standardize on it.� Insightful Life Sciences Solutions Provide the Knowledge to Act� Insightful provides life sciences organizations with the knowledge they need to drive faster, better decisions with specialized analytics, graphics and reporting formats. Insightful offers predictive analytic software and service solutions in clinical graphics, PK/PD reporting, clinical data review, innovative trial design, and safety data mining. These solutions are designed to act in concert with existing data management and workflow systems within validated environments to speed the analysis and reporting processes, to increase the likelihood of discerning safety and efficacy signals earlier in the development lifecycle. ABOUT MEDICAL PROGNOSIS INSTITUTE Headquartered in H�rsholm, Denmark, Medical Prognosis Institute�s (MPI) mission is to improve cancer treatment with leading-edge technology based on DNA microarrays. MPI uses proprietary individualized genomic profiling of tumor tissue for prognostication of individual patients and for determining which cancer patients will benefit from which specific chemotherapy and/or radiation therapy. MPI is currently conducting clinical trials to validate its claims that its products and services will give cancer patients and oncologists necessary insight to help make better treatment decisions. In addition, MPI recently began providing its fast turn-around, high-quality DNA microarray services on a fee-for-service basis to the academic and biopharmaceutical industry in the discovery phase. For more information, visit www.medical-prognosis.com, email info@medical-prognosis.com or call +45 40862156. ABOUT INSIGHTFUL CORPORATION Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions. Insightful products S-PLUS�, Insightful Miner� and S-PLUS� Enterprise Server allow companies to perform sophisticated statistical data analysis and data mining and create high-quality graphics and reports. Insightful has been delivering industry-leading, high-ROI solutions to thousands of companies in financial services, life sciences, telecommunications, and manufacturing, plus government and research institutions, for 20 years. Headquartered in Seattle, Insightful has offices in New York, North Carolina, the United Kingdom, Switzerland, France and Hong Kong, with distributors around the world. For more information, visit www.insightful.com, email info@insightful.com or call 1-800-569-0123. Note to Investors � Forward Looking Statements This press release contains forward-looking statements, including statements about the potential performance and advantages of our life sciences solutions and their potential value to MPI and other customers. Forward-looking statements are based on the judgment and opinions of management at the time the statements are made. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed or implied by the forward-looking statements for a number of reasons, including, without limitation, the risk that our products do not perform as designed and expected. More detailed information regarding these and other factors that could affect actual results is set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-KSB. You should not unduly rely on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of anticipated events.